Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 9/20 | 0.51 |
| ▸ | CA2 | P00918 | 9/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832942 | 1.00 | TDP1 (0.63) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL29154833 | 0.98 | MEN1 (0.61) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL21985071 | 0.98 | MEN1 (0.61) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL30163663 | 0.98 | MEN1 (0.61) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL2917277 | 0.93 | MEN1 (0.68) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL24664899 | 0.87 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL18857298 | 0.87 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL6848535 | 0.87 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL28219956 | 0.86 | MEN1 (0.57) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL1654204 | 0.86 | MEN1 (0.57) | TDP1MEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306372-B1 | HETEROCYCLE DERIVATIVES AND DRUGS | NIPPON SHINYAKU CO LTD (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-6794389-B2 | Quinazoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | TDP1 3703/4885MEN1 4755/4885KMT2A 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.